REGN looking very strong today after dropping just a bit on yesterdays market retreat following its big bump on Wednesday from the good news. Frist they got
approval of Eylea before the PDFUA date. More importantly they also
bought that Priority Review voucher from BioMarin for $67.5M (halvsies with Sanofi) on Wednesday which may allow them to outflank AMGN by helping them to get Alirocumab, one of those new statin alternatives, to market several months sooner than expected.
Note that they report earnings next week (Aug 5th) so it will be interesting to see just how far this one runs in the next few days.
[disclosure: I'm holding a small position in the form of Aug and Nov calls]